The examination of the effect of L/N type calcium channel blocker for L-FABP in hypertensive patients with coronary arteries disease.

The examination of the effect of L/N type calcium channel blocker for L-FABP in hypertensive patients with coronary arteries disease. - The examination of the effect of L/N type calcium channel blocker for L-FABP in hypertensive patients with coronary arteries disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004679

Enrollment

100

Registered

2010-12-07

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive patients with coronary arteries disease.

Interventions

Cilnidipine group Amlodioine group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive patients(more than 140/90 mmHg or hypotensive agents treatment) undergoing scheduled coronary angiography.

Exclusion criteria

Exclusion criteria: 1)Pregnancy or a patient with the possibility 2)History of hypersensitivity to CCBs 3)Malignant hypertension 4)Patients who are inadequate to enter this study due to the other reasons by physician's judgments.

Design outcomes

Primary

Measure	Time frame
Changes in urinary L-FABP	—

Secondary

Measure	Time frame
Incidence of CIN(A increase at least 0.5mg/dL or a relative increase of at least 25% from baseline value) Blood pressure, heart rate, BUN, Cr(estimated GFR), proteinuria	—

Countries

Japan

Contacts

Public ContactHiromasa Katoh

Yokohama Sakae Kyosai Hospital Department of Internal medicine, Division of Cardiology

045-891-2171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026